论文部分内容阅读
目的观察康复新液联合泮托拉唑、阿莫西林、克拉霉素三联疗法治疗消化性溃疡(PU)的疗效。方法对照组给予患者泮托拉唑40 mg,qd,阿莫西林1000 mg+克拉霉素500 mg,bid,三联治疗7 d后,继续单用泮托拉唑40 mg,qd,连服3周。治疗组在对照组基础上,加服康复新液10 mL,tid,共4周。胃镜复查评估溃疡愈合、HP清除及1年后溃疡复发等情况。结果治疗组溃疡愈合率、总有效率、HP清除率分别为82.6%、95.7%、91.35%,对照组的分别为52.5%、85.0%、87.5%,HP根除率无明显差异(P>0.05)。两组均未出现明显不良反应。结论康复新液联合泮托拉唑三联疗法治消化性溃疡疗效可靠,值得推广应用。
Objective To observe the curative effect of Kangfuxin solution combined with pantoprazole, amoxicillin and clarithromycin triple therapy on peptic ulcer (PU). Methods Patients in the control group were treated with pantoprazole 40 mg qd, amoxicillin 1000 mg + clarithromycin 500 mg bid twice daily for 3 days after the triple therapy for 7 days. Treatment group on the basis of the control group, add new rehabilitation fluid 10 mL, tid, a total of 4 weeks. Gastroscopy review evaluation of ulcer healing, HP clearance and 1 year after the ulcer recurrence. Results The healing rate of ulcer, the total effective rate and the clearance rate of HP in the treatment group were 82.6%, 95.7% and 91.35% respectively, while those in the control group were 52.5%, 85.0% and 87.5% respectively. There was no significant difference in the eradication rate of HP (P> 0.05) . No significant adverse reactions occurred in both groups. Conclusion Kangfuxin solution combined with pantoprazole triple therapy in the treatment of peptic ulcer is reliable and should be widely applied.